UPCOMING SESSIONS in ET

Tue, Jun 2, 2026

5:00 – 6:00 AM Bangkok

Your Medical Notebook: Labs, Meds, Questions, Contacts & Care Info Tracey Silverstein Click Here To Register

UPCOMING SESSIONS in ET

Tue, Jun 2, 2026 · 5:00 – 6:00 AM Bangkok

Your Medical Notebook: Labs, Meds, Questions, Contacts & Care Info

Tracey Silverstein

Click Here To Register

View all sessions

A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

Published: Mar 23, 2026

Category

Clinical Trials and Research

Source

University of California Health

a study on AL Amyloidosis Amyloidosis

Open-label Phase 1b/2 study with primary objective of this study is to evaluate the safety, tolerability and efficacy of AZD0120 in participants with light chain (AL) amyloidosis.

News Url

Newsletter

RNAi Explained

Dr. Bersell explores RNA interference (RNAi) technology and its applications in treating ATTR-CM and ATTR-PN. Learn about mechanism of action, clinical evidence, and patient outcomes.

Expert Perspectives on Attruby®

Dr. Barry Trachtenberg and ATTR community members discuss Attruby™ (acoramidis), covering clinical data, patient perspectives, and treatment considerations.

Watch Discussion

Featured Trials